|Articles|August 1, 1999

August 1999
Volume 5
Issue 8

A Short-Term Cost-of-Treatment Model for Type 2 Diabetes: Comparison of Glipizide Gastrointestinal Therapeutic System, Metformin, and Acarbose

Author(s)Joe W. Ramsdell, MD, Joseph A. Grossman, MD, Jennifer M. Stevens, PharmD

Download PDF: A Short-Term Cost-of-Treatment Model for Type 2 Diabetes: Comparison of Glipizide Gastrointestinal Therapeutic System, Metformin, and Acarbose

Articles in this issue

over 26 years ago

Article

A Model for Improving Coverage Policy Decisions

over 26 years ago

Article

Exemplary Programs on Midlife Women's Health Issues in a Managed Care Setting

over 26 years ago

Article

The Impact of Relational Activities on HMO Organizational Outcomes

over 26 years ago

Article

Cartoid Endarterectomy: Improved Clinical Outcome and Reduced Length of Hospitalization

over 26 years ago

Article

HIV Infection in Adults: A Therapeutic Update

over 26 years ago

Article

To Cover or Not to Cover: How to Decide?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

A Short-Term Cost-of-Treatment Model for Type 2 Diabetes: Comparison of Glipizide Gastrointestinal Therapeutic System, Metformin, and Acarbose

Articles in this issue

Newsletter

Related Content

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

5 Things to Know About the Oral GLP-1 Era

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Even After 6 Years, Disease Progression Impacts Survival in Mantle Cell Lymphoma